Manejo farmacoterapéutico del paciente hospitalizado con enfermedad de Parkinson

236 p.

Prevalencia del síndrome metabólico en una población de niños obesos en el País Vasco, su relación con la resistencia a la insulina, las adipoquinas y grhelina

274 p. : graf.

Influence of nutrient intake on antioxidant capacity, muscle damage and white blood cell count in female soccer players

11 p.

Enfermedad de Parkinson por mutación vasca de la dardarina (LRRK2): estudio epidemiológico, clínico y genético

149 p.

Changes in white adipose tissue metabolism induced by resveratrol in rats

Background: A remarkable range of biological functions have been ascribed to resveratrol. Recently, this polyphenol has been shown to have body fat lowering effects. The aim of the present study was to assess some of the potential underlying mechanisms of action which take place in adipose tissue. Methods: Sixteen male Sprague-Dawley rats were randomly divided into two groups: control and treated with 30 mg resveratrol/kg body weight/d. All rats were fed an obesogenic diet and after six weeks of treatment white adipose tissues were dissected. Lipoprotein lipase activity was assessed by fluorimetry, acetyl-CoA carboxylase by radiometry, and malic enzyme, glucose-6P-dehydrogenase and fatty acid synthase by spectrophotometry. Gene expression levels of acetyl-CoA carboxylase, fatty acid synthase, lipoprotein lipase, hormone-sensitive lipase, adipose triglyceride lipase, PPAR-gamma, SREBP-1c and perilipin were assessed by Real time RT-PCR. The amount of resveratrol metabolites in adipose tissue was measured by chromatography. Results: There was no difference in the final body weight of the rats; however, adipose tissues were significantly decreased in the resveratrol-treated group. Resveratrol reduced the activity of lipogenic enzymes, as well as that of heparin-releasable lipoprotein lipase. Moreover, a significant reduction was induced by this polyphenol in hormone-sensitive lipase mRNA levels. No significant changes were observed in other genes. Total amount of resveratrol metabolites in adipose tissue was 2.66 +/- 0.55 nmol/g tissue. Conclusions: It can be proposed that the body fat-lowering effect of resveratrol is mediated, at least in part, by a reduction in fatty acid uptake from circulating triacylglycerols and also in de novo lipogenesis.

Regulación del síndrome de abstinencia a opiáceos por los sistemas de recaptación de glutamato

Máster de Farmacología “Desarrollo, Evaluación y Uso Racional de Medicamentos” - E-mail de la autora: amets88@hotmail.com

Telemonitorización en tiempo real del Síndrome de Apneas-Hipopneas del Sueño (SAHS) mediante pulsioximetría domiciliaria

191 p.

Estudio de la eficacia y seguridad de un dispositivo intraoral de avance mandibular en pacientes roncadores habituales con síndrome de apnea-hipopnea de carácter leve-moderado

184 p. : il.

Características clínicas en el Síndrome de Fibromialgia : asociación con la calidad de vida relacionada con la salud y contribución a la caracterización de subgrupos

251 p. : il.

Síndrome Postparada Cardiaca: una resivisión bibliográfica sistemática

Desde el desarrollo de la resucitación cardiopulmonar (RCP) y la optimización de los cuatro eslabones de la cadena de supervivencia, el número de pacientes que se recupera de la parada cardiaca (PC), recuperando la circulación espontánea ha aumentado considerablemente. Sin embargo, este mismo aumento de la supervivencia ha generado a su vez, una nueva condición clínica, conocida como Síndrome Post parada cardiaca (SPP), que es responsable de que un importante número de estos pacientes fallezca al de pocos días, generalmente por daño cerebral. Algunos autores han propuesto los cuidados postparada cardiaca como el quinto eslabón de la cadena de superviencia; pero, por ahora es el eslabón más débil y del que menos información disponemos. Objetivos: realizar una lectura crítica de las publicaciones sobre el SPP, sintetizando el material publicado hasta ahora e identificando los aspectos relevantes del mismo. Metodología: revisión bibliográfica sistemática a través de las bases de datos electrónicas: MedLine, PubMed, Crochane, Dialnet, Scopus, Cuiden. Resultados: en general, la calidad de los artículos revisados es baja debido, principalmente, a que la metodología utilizada para la selección y evaluación de los estudios individuales no está descrita en ninguno de ellos. Conclusiones: Aún existe escasa investigación sobre el SPP, y la mayoría de estudios publicados parten de los datos obtenidos en el artículo de consenso ILCOR 2008.

Morphofunctional changes in a rat model of Parkinson's disease - Effects of neurotrophic factors administration

255 p.

Diseño de un programa de Surf recreativo enfocado a colectivos con Síndrome de Down de 6 a 10 años

El objetivo de este trabajo es diseñar un programa de surf recreativo enfocado a colectivos con Síndrome de Down de 6 a 10 años. El Síndrome de Down se define como una discapacidad intelectual causada por una alteración en el par de cromosomas 21 (OMS, 2011). Resulta de especial relevancia el tratamiento de dicha discapacidad de manera no farmacológica, destacando la actividad física, en este caso el surf, como elemento inclusivo a nivel físico, psicológico y social. Se analizan distintos programas de Actividad Física en el medio acuático con personas con Síndrome de Down y se presenta el Surf como elemento que provoca grandes beneficios. A continuación se presenta el diseño de un programa que podría llevarse a cabo en un entorno cercano a nuestro territorio con un atractivo elevado ya que se trata de un proyecto innovador y beneficioso para personas con Síndrome de Down y sus familiares.

Epitope mapping of antibodies to alpha-synuclein in LRRK2 mutation carriers, idiopathic Parkinson disease patients, and healthy controls

Alpha-synuclein (Snca) plays a major role in Parkinson disease (PD). Circulating anti-Snca antibodies has been described in PD patients and healthy controls, but they have been poorly characterized. This study was designed to assess the prevalence of anti-Snca reactivity in human subjects carrying the LRRK2 mutation, idiopathic PD (iPD) patients, and healthy controls and to map the epitopes of the anti-Snca antibodies. Antibodies to Snca were detected by ELISA and immunoblotting using purified recombinant Snca in plasma from individuals carrying LRRK2 mutations (104), iPD patients (59), and healthy controls (83). Epitopes of antibodies were mapped using recombinant protein constructs comprising different regions of Snca. Clear positive anti-Snca reactivity showed no correlation with age, sex, years of evolution, or the disability scores for PD patients and anti-Snca reactivity was not prevalent in human patients with other neurological or autoimmune diseases. Thirteen of the positive individuals were carriers of LRRK2 mutations either non-manifesting (8 out 49 screened) or manifesting (5 positive out 55), three positive (out of 59) were iPD patients, and five positive (out of 83) were healthy controls. Epitope mapping showed that antibodies against the N-terminal (a.a. 1-60) or C-terminal (a.a. 109-140) regions of Snca predominate in LRRK2 mutation carriers and iPD patients, being N122 a critical amino acid for recognition by the anti-C-terminal directed antibodies. Anti-Snca circulating antibodies seem to cluster within families carrying the LRRK2 mutation indicating possible genetic or common environmental factors in the generation of anti-Snca antibodies. These results suggest that case-controls' studies are insufficient and further studies in family cohorts of patients and healthy controls should be undertaken, to progress in the understanding of the possible relationship of anti-Snca antibodies and PD patholog

Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease

The neurotransmitter serotonin (5-HT) has a multifaceted function in the modulation of information processing through the activation of multiple receptor families, including G-protein-coupled receptor subtypes (5-HT1, 5-HT2, 5-HT4-7) and ligand-gated ion channels (5-HT3). The largest population of serotonergic neurons is located in the midbrain, specifically in the raphe nuclei. Although the medial and dorsal raphe nucleus (DRN) share common projecting areas, in the basal ganglia (BG) nuclei serotonergic innervations come mainly from the DRN. The BG are a highly organized network of subcortical nuclei composed of the striatum (caudate and putamen), subthalamic nucleus (STN), internal and external globus pallidus (or entopeduncular nucleus in rodents, GPi/EP and GPe) and substantia nigra (pars compacta, SNc, and pars reticulata, SNr). The BG are part of the cortico-BG-thalamic circuits, which play a role in many functions like motor control, emotion, and cognition and are critically involved in diseases such as Parkinson's disease (PD). This review provides an overview of serotonergic modulation of the BG at the functional level and a discussion of how this interaction may be relevant to treating PD and the motor complications induced by chronic treatment with L-DOPA.